FDA grants orphan drug designation to aTyr Pharma's efzofitimod for systemic sclerosis

aTYR PHARMA INC

FDA granted orphan drug designation for efzofitimod to treat systemic sclerosis (scleroderma) on April 12, 2022.
Orphan designation may provide 7-year market exclusivity, tax credits, and waiver of FDA fees.
Efzofitimod is aTyr's lead therapeutic candidate; this designation supports its development program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.